Investment Analysts’ Recent Ratings Changes for Cencora (COR)

A number of research firms have changed their ratings and price targets for Cencora (NYSE: COR):

• 11/7/2024 – Cencora had its price target raised by analysts at Barclays PLC from $263.00 to $290.00. They now have an “overweight” rating on the stock.
• 11/7/2024 – Cencora had its price target raised by analysts at Robert W. Baird from $287.00 to $292.00. They now have an “outperform” rating on the stock.
• 11/7/2024 – Cencora had its price target raised by analysts at Evercore ISI from $250.00 to $285.00. They now have an “outperform” rating on the stock.
• 11/7/2024 – Cencora had its price target raised by analysts at UBS Group AG from $275.00 to $285.00. They now have a “buy” rating on the stock.
• 10/8/2024 – Cencora had its price target lowered by analysts at Evercore ISI from $270.00 to $250.00. They now have an “outperform” rating on the stock.
• 10/7/2024 – Cencora had its price target lowered by analysts at Leerink Partners from $277.00 to $275.00. They now have an “outperform” rating on the stock.
• 9/20/2024 – Cencora was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 9/18/2024 – Cencora had its “neutral” rating reaffirmed by analysts at Bank of America Co.. They now have a $245.00 price target on the stock, down previously from $275.00.

Cencora Stock Up 0.5 %

Cencora stock traded up $1.16 during trading hours on Wednesday, hitting $249.95. The company had a trading volume of 1,255,500 shares, compared to its average volume of 1,407,809. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. Cencora, Inc. has a fifty-two week low of $191.11 and a fifty-two week high of $251.56. The firm’s fifty day moving average is $232.24 and its 200-day moving average is $230.86. The firm has a market capitalization of $49.25 billion, a P/E ratio of 33.28, a price-to-earnings-growth ratio of 1.66 and a beta of 0.44.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.88%. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. Cencora’s dividend payout ratio is presently 27.16%.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 15.80% of the company’s stock.

Institutional Trading of Cencora

Hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD acquired a new stake in Cencora during the first quarter valued at approximately $2,183,619,000. JPMorgan Chase & Co. acquired a new position in shares of Cencora during the first quarter valued at $1,199,695,000. Boston Partners bought a new position in shares of Cencora in the 1st quarter valued at about $1,001,269,000. Capital Research Global Investors bought a new position in Cencora in the first quarter valued at approximately $650,424,000. Finally, Bessemer Group Inc. bought a new position in shares of Cencora in the 1st quarter worth $556,245,000. Institutional investors own 97.52% of the company’s stock.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.